Institutional members access full text with Ovid®

Share this article on:

Tranexamic Acid Treatment for Heavy Menstrual Bleeding: A Randomized Controlled Trial

Lukes, Andrea S. MD, MHSc; Moore, Keith PharmD; Edlund, Mans MD

doi: 10.1097/AOG.0b013e3182041e28
Departments: Letters to the Editor

CWRWC, Durham North Carolina (Lukes)

Xanodyne Pharmaceuticals, Newport, Kentucky (Moore)

Karolinska Hospital, Stockholm, Sweden (Edlund)

Financial Disclosure: Dr. Lukes receives or has received research support from Xanodyne, Ethicon, Merck, Bayer, Luitpold, Hologic, National Improvement for Women's Healthcare, Duramed, NIH, CDC/ATPR, Smith & Nephew, Trent Foundation, and AMS. She consults with and/or has served on speakers' bureaus for Ferring, Xanodyne, Hologic, AMS, Bayer, Interlace Medical, Ethicon, Boehinger Ingelheim, Myriad, Microsulis (5 years ago), AMAG (4 years ago), and Daichii. Dr. Moore is an employee of Xanodyne. Dr. Edlund receives or has received research support from Kabi Pharmacia, Pharmacia & Upjohn, and Ferring. He consults with Ferring, AstraZeneca, Bayer Schering, and Xanodyne. He has given expert testimony regarding U.S. Food and Drug Administration (FDA) approval.

© 2011 The American College of Obstetricians and Gynecologists